A theoretical investigation into post-operative, intracavitary beta therapy of high-grade glioblastomas using yttrium-90

Physics in Medicine and Biology

Volumn 51, Issue 20, 2006, Pages 5377-5389

  Stefanou, S S ^a   Sparks, R B ^b   Dale, R G ^c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b CDE Dosimetry Services Inc   (United States)

^c IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LINEAR QUADRATIC (LQ); MALIGNANT GLIOBLASTOMA; RADIOSENSITIVITIES;

BIOLOGICAL ORGANS; CELLS; MATHEMATICAL MODELS; MEDICAL PROBLEMS; TUMORS; YTTRIUM;

RADIOTHERAPY;

YTTRIUM 90;

ARTICLE; CANCER RADIOTHERAPY; CELL DENSITY; DIFFUSION; DOSE RESPONSE; DOSIMETRY; ELECTRON THERAPY; GLIOBLASTOMA; LINEAR QUADRATIC MODEL; MATHEMATICAL MODEL; MONTE CARLO METHOD; NEUTRON; PHOTON; POSTOPERATIVE CARE; PRIORITY JOURNAL; RADIATION DOSE; RADIOBIOLOGY; RADIOSENSITIVITY; TUMOR CELL;

APOPTOSIS; BETA PARTICLES; BETA RAYS; CELL PROLIFERATION; CELL SURVIVAL; COMPUTER SIMULATION; GLIOBLASTOMA; HUMANS; INJECTIONS, INTRALESIONAL; MODELS, BIOLOGICAL; POSTOPERATIVE CARE; RADIOMETRY; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RELATIVE BIOLOGICAL EFFECTIVENESS; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 33749589093     PISSN: 00319155     EISSN: 13616560     Source Type: Journal    
DOI: 10.1088/0031-9155/51/20/020     Document Type: Article

References (22)

1. Akabani G, McLendon R E, Bigner D D and Zalutsky M R 2002 Vascular-targeted endoradiotherapy of tumours using alpha-emitting compounds: theoretical analysis Int. J. Radiat. Oncol. Biol. Phys. 46 947-58
2. 103 Pd 2001 Phys. Med. Biol. 46 2557-69
3. Barendsen G W 1982 Dose fractionation, dose-rate and iso-effect relationships for normal tissue responses Int. J. Radiat. Oncol. Biol. Phys. 8 1981-97
4. Barth R F 2003 A critical assessment of boron neutron capture therapy: an overview J. Neurooncol. 62 1-5
5. Briesmeister J F (ed) 1997 MCNP-a general Monte Carlo N-particle transport code LA-12625-M, Version 4B (Los Alamos, NM: Los Alamos National Laboratory) ACC: MOL.19980624.0328
6. Burgess P K, Kulesa P M, Murray J D and Alvard E C 1997 The interaction of growth rates and diffusion coefficients in a three dimensional mathematical model of gliomas J. Neuropathol. Exp. Neurol. 56 704-13
7. Cristy M and Eckerman K 1987 Specific absorbed fractions of energy at various ages from internal photons sources Report ORNL/TM-8381 V1-V7 (Oak Ridge, TN: Oak Ridge National Laboratory)
8. Dale R G 1985 The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy Br. J. Radiol. 58 515-28
9. Eckerman K F, Westfall R J, Ryman J C and Cristy M 1994 Availability of nuclear decay data in electronic form, including beta spectra not previously published Health Phys. 67 338-45
10. Goetz C, Riva P, Poepperl G, Gildehaus F J, Hischa A, Tatsch K and Reulen H J 2003 Locoregional radioimmunotherapy in selected patients with malignant glioma: experiences, side effects and survival times J. Neurooncol. 62 321-8
11. Hopkins K, Papanastassiou V, Zananiri F A F and Kemshead J T 1997 A model to estimate the dose to tumour following intracavity administration of radioimmunoconjugates to patients with malignant gliomas Br. J. Radiol. 70 1152-61
12. Jones B and Dale R G 2005 The potential for mathematical modelling in the assessment of the radiation dose equivalent of cytotoxic chemotherapy given concomitantly with radiotherapy Br. J. Radiol. 78 939-44
13. Kaal E C and Vecht C J 2004 The management of brain edema in brain tumours Curr. Opin. Oncol. 16 593-600
14. Loevinger R, Budinger T F and Watson E E (ed) 1991 MIRD Primer for Absorbed Dose Calculations Revised (New York: Society of Nuclear Medicine)
15. Mariani G et al 1997 A pilot pharmacokinetic and immunoscinigraphic study with the technetium-99m-labelled monoclonal antibody BC-1 directed against oncofetal fibronectin in patients with brain tumors Cancer 80 (Suppl. 12) 2484-9
16. Munro T R and Gilbert T C 1961 The relation between tumour lethal dose and the radiosensitivity of tumour cells Br. J. Radiol. 34 246-51
17. Riva P et al 1999 Loco-regional radioimmunotherapy of high-grade malignant gliomas using specific monoclonal antibodies labeled with Y-90: a phase I study Clin. Cancer Res. 5 (Suppl.) 3275s-80s
18. Riva P, Franceschi G, Riva N, Casi M, Santimaria M and Adamo M 2000 Role of nuclear medicine in the treatment of malignant gliomas: the locoregional radioimmunotherapy approach Eur. J. Nucl. Med. 27 601-9
19. Stewart L A 2002 Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient from 12 randomised trials Lancet 359 1011-8
20. Wigg D R 2001 Applied Radiobiology and Bioeffect Planning (Madison, WI: Medical Physics Publishing)
21. Zalutsky M R 2004 Targeted radiotherapy and brain tumours Br. J. Cancer 90 1469-73
22. Zalutsky M R 2005 Current status of therapy of solid tumours: brain tumour therapy J. Nucl. Med. 46 151S-156S